2024 World Conference on Lung Cancer (WCLC) - Posters-P1.12B.09 Efficacy of Selpercatinib by RET Fusion Partner in RET+ NSCLC: Results from the LIBRETTO-001 and LIBRETTO-431 Trials

P1.12B.09 Efficacy of Selpercatinib by RET Fusion Partner in RET+ NSCLC: Results from the LIBRETTO-001 and LIBRETTO-431 Trials

Back to course

Pdf Summary

This document summarizes findings from studies evaluating the efficacy of selpercatinib, a selective RET inhibitor, in treating advanced RET fusion-positive non-small cell lung cancer (NSCLC). The analysis pooled data from the LIBRETTO-001 and LIBRETTO-431 clinical trials, assessing the impact of different RET fusion partners on the efficacy of selpercatinib.<br /><br />Key findings include that selpercatinib showed robust and durable efficacy regardless of the RET fusion partner. However, patients with the KIF5B-RET fusion had poorer progression-free survival (PFS) compared to those with CCDC6-RET fusions. Despite this, selpercatinib improved clinical outcomes over alternative treatments like chemotherapy with or without pembrolizumab.<br /><br />Multivariate analyses identified RET fusion type (KIF5B vs. CCDC6) as a significant prognostic factor for PFS and overall response rate (ORR) among selpercatinib-treated patients. The CCDC6-RET group displayed superior PFS and higher ORR than the KIF5B-RET group. Additionally, regardless of the fusion partner, treatment-naïve patients showed better response rates than those with prior treatments.<br /><br />These results support the early identification of RET fusions through comprehensive genomic testing, with selpercatinib as a recommended first-line therapy for patients with advanced RET NSCLC. The study emphasizes the importance of assessing fusion partners in tailoring treatment plans for improved patient outcomes.<br /><br />The data was presented at the International Association for the Study of Lung Cancer 25th World Conference on Lung Cancer in 2024. The research was conducted across multiple institutions internationally with sponsorship by Eli Lilly and Company.

Asset Subtitle

Ben Solomon

Meta Tag

Speaker Ben Solomon

Topic Metastatic NSCLC – Targeted Therapy

Keywords

selpercatinib

RET inhibitor

non-small cell lung cancer

NSCLC

RET fusion

LIBRETTO-001

LIBRETTO-431

progression-free survival

KIF5B-RET

CCDC6-RET